Evidence map›Paper›PMID 41145814›Full record

ArticleProstate cancer and prostatic diseases2026

Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancer.

Autumn Gagnon, Caiwei Zhong, Wanling Xie, Lynne Morlock, Dory Freeman, Rachel Trowbridge, Kerry L Kilbridge, Bradley A McGregor, Mary-Ellen Taplin, Atish D Choudhury

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Autumn GagnonDana-Farber Cancer Institute, Boston, MA, USA.
Caiwei ZhongDana-Farber Cancer Institute, Boston, MA, USA.
Wanling XieDana-Farber Cancer Institute, Boston, MA, USA.
Lynne MorlockDana-Farber Cancer Institute, Boston, MA, USA.
Dory FreemanMGH Institute of Health Professions, Boston, MA, USA.
Rachel TrowbridgeDana-Farber Cancer Institute, Boston, MA, USA.
Kerry L KilbridgeDana-Farber Cancer Institute, Boston, MA, USA.
Bradley A McGregorDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8298-0289
Mary-Ellen TaplinDana-Farber Cancer Institute, Boston, MA, USA.
Atish D ChoudhuryDana-Farber Cancer Institute, Boston, MA, USA. atish_choudhury@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-9344-6631

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAbiraterone acetate/prednisone (AAP) plus a luteinizing hormone releasing hormone agonist or antagonist (LHRH-A) is commonly used for treating high risk M0 or oligometastatic prostate cancer, but prolonged LHRH-A can be associated with delayed and incomplete testosterone (T) recovery after discontinuation.

methodsWe assessed impact of earlier LHRH-A discontinuation prior to stopping AAP on testosterone recovery (TR) to ≥150 ng/dl in an institutional cohort of patients who received 500-800 days of treatment.

results100% (89/89) had testosterone <20 ng/dl at AAP end of treatment, and discontinuing LHRH-A ≥ 12 months prior to stopping AAP demonstrated improvement in 6-month TR (76.9%, 95% CI 39.7-92.8) compared to <3 months prior to stopping AAP (13.0%, 95% CI 4.7-25.8; HR 0.27[0.11-0.66], p < 0.01).

conclusionsEarly LHRH-A discontinuation 12 months or more prior to stopping AAP is associated with faster and more frequent T recovery compared to LHRH-A discontinuation within 3 months of AAP cessation, with T levels remaining appropriately suppressed during abiraterone monotherapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsGonadotropin-Releasing HormonePrednisoneProstatic NeoplasmsTestosteroneAbiraterone AcetateAgedAged, 80 and overAndrostenesHumansMaleMiddle AgedTreatment OutcomeabirateroneAbiraterone AcetateAndrostenesGonadotropin-Releasing HormonePrednisoneTestosterone

Identifiers

PMID41145814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.